ORIFARM GENERICS A/S: Financial statements 2014
CVR: 25674030
Source: annual report 2014, Danish Business Authority
01/01/2014 – 31/12/2014
ORIFARM GENERICS A/S (CVR 25674030) has filed annual accounts for 2014. In 2014, the company reported a gross profit of DKK 32,083,000 and a net result of DKK 550,000 compared with DKK 1,324,000 the year before. That is an increase of 4.5% compared with the year before. Equity in the 2014 report amounted to DKK 7,432,000. The solvency ratio was 23.8%.
- Gross Profit
- DKK 32,083,000
- Profit/Loss
- DKK 550,000
- Equity
- DKK 7,432,000
- Total Assets
- DKK 31,290,000
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2014 | - | 32.1 mio. | 550 t. | 7.4 mio. | - |
| 2013 | - | 30.7 mio. | 1.3 mio. | 6.9 mio. | - |
Official annual report
Screen every Danish company
Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.
Try company screeningEvents in 2014
ORIFARM GENERICS A/S has published its annual report for 2013. Gross profit came to DKK 30,716,000, and the net result was DKK 1,324,000.
As of April 8, 2014, Erik Sandberg has joined the board of directors of ORIFARM GENERICS A/S.
As of April 8, 2014, Hans Christian Eberhard Groth Teisen has left the board of directors of ORIFARM GENERICS A/S.
About ORIFARM GENERICS A/S
ORIFARM GENERICS A/S is a Danish company of the type Aktieselskab based in Odense S, founded in 2000. The company is registered under the industry Engroshandel med læge- og hospitalsartikler. The company was previously named COPYFARM A/S and A/S PSE 38 NR. 2228. The management consists of Thomas Brandhof. The board consists of Hans Carl Bøgh-Sørensen (chair), Birgitte Bøgh-Sørensen, Mads Fink Eriksen and Nicki Lund Kristensen. The company is owned by ORIFARM GENERICS HOLDING A/S. The company has 255 employees (2026). In 2025, the company reported revenue of DKK 2,463,585,000 and a net result of DKK 77,177,000 compared with DKK 59,860,000 the year before. Equity in the 2025 report amounted to DKK 496,304,000.